GlobeNewswire by notified

Orion Corporation: Managers’ transactions – Kari Jussi Aho

Share

ORION CORPORATION
MANAGERS’ TRANSACTIONS
9 MARCH 2023 at 11.30 EET

Orion Corporation: Managers’ transactions – Kari Jussi Aho

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Kari Jussi Aho
Position: Member of the Board/Deputy member
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 26870/7/10

____________________________________________
Transaction date: 2023-03-07
Venue: CEUD
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 2 Unit price: 44.375 EUR
(2): Volume: 75 Unit price: 44.4 EUR

Aggregated transactions (2):
Volume: 77 Volume weighted average price: 44.39935 EUR
____________________________________________
Transaction date: 2023-03-07
Venue: DHEL
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 6 Unit price: 44.35 EUR

Aggregated transactions (1):
Volume: 6 Volume weighted average price: 44.35 EUR
____________________________________________
Transaction date: 2023-03-07
Venue: TQEM
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 2 Unit price: 44.375 EUR

Aggregated transactions (1):
Volume: 2 Volume weighted average price: 44.375 EUR
____________________________________________
Transaction date: 2023-03-07
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 1 Unit price: 44.35 EUR
(2): Volume: 2 Unit price: 44.35 EUR
(3): Volume: 6 Unit price: 44.35 EUR
(4): Volume: 4 Unit price: 44.35 EUR
(5): Volume: 1 Unit price: 44.4 EUR
(6): Volume: 46 Unit price: 44.4 EUR
(7): Volume: 2 Unit price: 44.4 EUR

Aggregated transactions (7):
Volume: 62 Volume weighted average price: 44.38952 EUR
____________________________________________
Transaction date: 2023-03-08
Venue: BEUP
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 16 Unit price: 44.625 EUR
(2): Volume: 16 Unit price: 44.65 EUR
(3): Volume: 34 Unit price: 44.65 EUR

Aggregated transactions (3):
Volume: 66 Volume weighted average price: 44.64394 EUR
____________________________________________
Transaction date: 2023-03-08
Venue: CEUX
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 41 Unit price: 44.8 EUR
(2): Volume: 40 Unit price: 44.55 EUR
(3): Volume: 42 Unit price: 44.55 EUR

Aggregated transactions (3):
Volume: 123 Volume weighted average price: 44.63333 EUR
____________________________________________
Transaction date: 2023-03-08
Venue: DHEL
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 8 Unit price: 44.375 EUR
(2): Volume: 75 Unit price: 44.275 EUR
(3): Volume: 3 Unit price: 44.275 EUR
(4): Volume: 35 Unit price: 44.275 EUR

Aggregated transactions (4):
Volume: 121 Volume weighted average price: 44.28161 EUR
____________________________________________
Transaction date: 2023-03-08
Venue: TQEM
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 63 Unit price: 44.65 EUR
(2): Volume: 234 Unit price: 44.475 EUR
(3): Volume: 69 Unit price: 44.35 EUR
(4): Volume: 191 Unit price: 44.35 EUR

Aggregated transactions (4):
Volume: 557 Volume weighted average price: 44.43645 EUR
____________________________________________
Transaction date: 2023-03-08
Venue: TQEX
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 41 Unit price: 44.55 EUR

Aggregated transactions (1):
Volume: 41 Volume weighted average price: 44.55 EUR
____________________________________________
Transaction date: 2023-03-08
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014369
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 32 Unit price: 44.8 EUR
(2): Volume: 144 Unit price: 44.7 EUR
(3): Volume: 1 Unit price: 44.65 EUR
(4): Volume: 3 Unit price: 44.65 EUR
(5): Volume: 150 Unit price: 44.65 EUR
(6): Volume: 299 Unit price: 44.55 EUR
(7): Volume: 35 Unit price: 44.35 EUR
(8): Volume: 55 Unit price: 44.35 EUR
(9): Volume: 65 Unit price: 44.45 EUR
(10): Volume: 10 Unit price: 44.45 EUR
(11): Volume: 29 Unit price: 44.45 EUR
(12): Volume: 150 Unit price: 44.45 EUR
(13): Volume: 9 Unit price: 44.45 EUR
(14): Volume: 150 Unit price: 44.45 EUR
(15): Volume: 11 Unit price: 44.4 EUR
(16): Volume: 150 Unit price: 44.4 EUR
(17): Volume: 13 Unit price: 44.4 EUR
(18): Volume: 150 Unit price: 44.4 EUR
(19): Volume: 17 Unit price: 44.35 EUR
(20): Volume: 150 Unit price: 44.35 EUR
(21): Volume: 150 Unit price: 44.35 EUR
(22): Volume: 150 Unit price: 44.35 EUR
(23): Volume: 9 Unit price: 44.35 EUR
(24): Volume: 18 Unit price: 44.35 EUR
(25): Volume: 150 Unit price: 44.35 EUR
(26): Volume: 9 Unit price: 44.35 EUR
(27): Volume: 150 Unit price: 44.35 EUR
(28): Volume: 2 Unit price: 44.35 EUR
(29): Volume: 18 Unit price: 44.3 EUR
(30): Volume: 8 Unit price: 44.3 EUR
(31): Volume: 11 Unit price: 44.3 EUR
(32): Volume: 1 Unit price: 44.3 EUR
(33): Volume: 2 Unit price: 44.3 EUR
(34): Volume: 5 Unit price: 44.3 EUR
(35): Volume: 12 Unit price: 44.3 EUR
(36): Volume: 99 Unit price: 44.3 EUR
(37): Volume: 19 Unit price: 44.3 EUR
(38): Volume: 9 Unit price: 44.3 EUR

Aggregated transactions (38):
Volume: 2445 Volume weighted average price: 44.43961 EUR

Orion Corporation

Liisa Hurme

President and CEO
Olli Huotari

SVP, Corporate Functions

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Baltic Horizon Fund consolidated audited results for 202329.3.2024 10:35:00 CET | Press release

Management Board of Northern Horizon Capital AS has approved the audited financial results of Baltic Horizon Fund (the Fund) for the year 2023. The financial results remained unchanged compared to the preliminary disclosure on 15 February 2024. Executing our strategy In a challenging economic landscape characterized by inflation, interest rate volatility, and recent geopolitical events, the Fund has assessed various strategic options to navigate these complexities and ensure future growth. Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from the centrally located ‘Modern City Life’ multi-fu

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

HiddenA line styled icon from Orion Icon Library.Eye